Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function, patient and graft survival, and cardiovascular surrogate markers during the first five years after transplantation.

Trial Profile

Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function, patient and graft survival, and cardiovascular surrogate markers during the first five years after transplantation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Methylprednisolone; Methylprednisolone; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms CISTCERT
  • Most Recent Events

    • 18 Jan 2017 Status changed from recruiting to completed.
    • 24 Mar 2012 Official Title amended as reported by European Clinical Trials Database record.
    • 09 Dec 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top